Sanoj Punnen Archives

Integrated Diagnostics for Risk Stratification and Active Surveillance

Posted by Sanoj Punnen, MD, MAS | Dec 2024

Sanoj Punnen, MD, discusses integrated diagnostics for risk stratification and active surveillance in prostate cancer.

Liquid Biomarkers and MRI in Prostate Cancer – Complementary?

Posted by Sanoj Punnen, MD, MAS | Mar 2023

Sanoj Punnen, MD, MAS, discusses the complementary use of liquid biomarkers and magnetic resonance imaging (MRI) in prostate cancer diagnosis.

Integrated Multi-Modality Diagnostic Evaluation of Prostate Cancer

Posted by Sanoj Punnen, MD, MAS | Mar 2021

Sanoj Punnen, MD, MAS, Associate Professor of Clinical Urology in the University of Miami Health System, explains how multimodal detection options could improve and personalize prostate cancer diagnosis, specifically the combination of MRI and biomarkers. He reviews the pros and cons of each option, noting incidence and mortality rates. To bolster his points, Dr. Punnen summarizes data from the PRECISION trial and the PROMIS trial. He also looks at a 2018 trial studying MRI and 4Kscore® for significant prostate cancer detection and a 2021 study that developed a 4Kscore®/MRI‐based tool to assist clinicians in biopsy decision‐making and counseling of those at risk for prostate cancer. Dr. Punnen concludes by calling for further research, specifically studies comparing biomarkers head-to-head and trials focusing on PET imaging and quantitative imaging.

Integrating MRI and Molecular Markers to Detect Aggressive Prostate Cancer

Posted by Sanoj Punnen, MD, MAS | Apr 2020

Sanoj Punnen, MD, MAS, Associate Professor of Clinical Urology in the University of Miami Health System, describes how recent trial based research has supported the synergistic qualities of MRI and biomarkers in the cancer detection process by reducing unnecessary biopsies by approximately 25%. He notes that more research is needed to declare an ideal procedure as well as what biomarkers are most efficient. Introducing MRI reading AI by the name Habitat Risk Scoring System, he highlights his own research which could alter how MRIs are processed and increase NPV to 92% without the use of biopsy.

Radiogenomics in Active Surveillance: How Can We Integrate mpMRI and Genomics to Monitor Prostate Cancer

Posted by Sanoj Punnen, MD, MAS | Nov 2019

Sanoj Punnen, MD, MAS, discusses the limitations of multiparametric MRI (mpMRI) and genomic biomarkers in selecting men with intermediate or high-risk prostate cancer for active surveillance. He suggests that combining mpMRI and genomics may allow for more accurate risk-stratification, focusing on preliminary data from the Miami MAST trial.